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Abstract Venous thromboembolism (VTE) is a highly
prevalent complication of malignancy with emerging
changes in incidence, diagnosis and treatment paradigms.
This manuscript, initiated by the Anticoagulation Forum,
provides clinical guidance based on existing guidelines and
consensus expert opinion where guidelines are lacking. We
address a) the appropriate workup to search for occult
malignancy in patients with idiopathic VTE, b) identifica-
tion of high-risk cancer patients for primary thrombopro-
phylaxis, c) the appropriate immediate and long-term
treatment for people with cancer diagnosed with acute
thromboembolism, d) the appropriate duration of antico-
agulation and e) the appropriate treatment strategy in
patients with recurrent VTE on anticoagulation. Areas of
controversy and future directions in this field are
highlighted.
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Introduction
Thromboembolism frequently complicates the course of
malignancy, particularly in the setting of medical and
surgical anti-cancer treatments [1]. It can involve both the
venous and arterial systems. The more common events are
venous thromboembolism (VTE), including deep venous
thrombosis (DVT) and pulmonary embolism (PE). VTE
generally presents after the diagnosis of cancer but it can be
the presenting symptom that leads to diagnosis of malig-
nancy. Incidentally diagnosed VTE, particularly involving
visceral or splanchnic veins such as the portal or superior
mesenteric vein, are increasingly contributing to the burden
of cancer-associated thrombosis [2]. Arterial events, such
as stroke or myocardial infarction, are also much more
prevalent in patients with malignancy, as compared to the
general population.
Thrombosis in cancer patients is associated with dele-
terious consequences. Most important is the strong asso-
ciation with short- and long-term mortality; indeed,
thromboembolism is the second-leading cause of death in
patients with malignancy [3, 4]. VTE is also associated
with recurrent VTE as well as bleeding, both at signifi-
cantly higher rates than seen in non-cancer patients [3].
Finally, VTE is associated with a threefold increase in
hospitalizations and higher total health care costs [5]. Thus,
appropriate prevention and treatment of cancer-associated
thrombosis is vital to reduce its burden on patients with
malignancy and on the health system at large. This chap-
ter will provide guidance on important clinical questions
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regarding risk assessment, primary prevention and treat-
ment of cancer-associated VTE.
Current guidelines and controversies
There has been a recent explosion of information regarding
cancer-associated thrombosis; a PubMed keyword search
identifies over 4600 published papers in just the past
5 years. Despite this wealth of knowledge, there remain
several areas of controversy and incomplete knowledge.
Although it is well recognized that VTE can be a presen-
tation of occult malignancy, the breadth and depth of work-
up to be initiated to search for occult cancer in a patient
with unprovoked VTE is unclear. Second, despite the high
overall prevalence of VTE in malignancy, there is wide
variation amongst specific subgroups of cancer patients.
Therefore, although primary prevention has been shown to
be successful in various randomized trials, prophylaxis
strategies need to be targeted toward those patients at
highest risk. Selection of such patients is an important and
controversial issue. Although current guidelines by the
American Society of Clinical Oncology (ASCO), the
European Society of Medical Oncology (ESMO) and the
National Comprehensive Cancer Network (NCCN), are
united in considering outpatient primary prophylaxis,
patient selection strategies are not well-defined [6–8].
Next, the patient-friendly direct oral anticoagulants
(DOACs) may offer an attractive alternative to other
therapies; however, data in cancer patients and direct
comparisons to the current standard of care with low
molecular weight heparin (LMWH) are limited. Finally,
little is known about the optimal duration of VTE treatment
in malignancy or how to treat patients who experience
recurrent thrombosis despite LMWH.
Methods
To provide guidance on the prevention and treatment of
cancer-associated thrombosis, we first developed a number
of pivotal practical questions pertaining to the topic
(Table 1). Questions were developed by consensus from
the authors. The literature addressing the above questions
was reviewed by searching electronic databases (PubMed,
Medline), with a focus on high quality cohort studies and
randomized controlled trials published in the last 10 years,
where available, as well as on recent systematic reviews.
For each question, a brief summary and interpretation of
pertinent literature and existing guidelines, where avail-
able, are provided, followed by guidance to the reader.
Guidance
(1) What is the appropriate workup to search for occult
malignancy in patients with idiopathic VTE?
Patients with acute unprovoked VTE have a four-fold
increased risk of having an underlying occult cancer
compared to patients with provoking (e.g. recent surgery)
risk factors [9]. Up to 10 % of patients with unprovoked
VTE may be diagnosed with cancer within the first year
following their thrombotic event [9]. The greatest period of
detection is within the first 6 months [9–11] and the most
frequently observed tumor types are cancers of the ovary,
pancreas and liver [11]. The long term cumulative inci-
dence of cancer diagnosis (i.e. beyond 6–12 months) has
been reported to be comparable to the incidence described
in the general population [12]. These data notwithstanding,
the utility and extent of occult cancer screening is con-
troversial. There is presently no consensus and wide vari-
ation in clinical practice regarding whether to perform
occult cancer screening and what investigations should be
included. The most recent version of the American College
of Chest Physicians (ACCP) clinical practice guidelines
does not provide a specific recommendation of occult
cancer screening in patients with unprovoked VTE.
Whereas some studies have suggested that a limited
occult cancer screening strategy, including medical history
taking, physical examination, routine blood tests and a
chest-X ray, is adequate to detect most occult cancers in
patients with unprovoked VTE, others have shown that a
more extensive occult cancer screening strategy (e.g.
ultrasonography and/or computed tomography (CT) of the
abdomen/pelvis, tumor markers, etc.) can increase the rate
of detection and improve the sensitivity of screening. Only
two studies have directly compared limited and extensive
screening [13, 14]. A recent prospective cohort study
comparing a limited occult cancer screening strategy to a
strategy also including a mammography in women and
thoracic and abdominal CT did not show any difference in
Table 1 Guidance questions to be considered
1. What is the appropriate workup to search for occult malignancy
in patients with idiopathic VTE?
2. How can high-risk cancer patients be identified for primary
thromboprophylaxis?
3. What is the appropriate immediate and long-term treatment for
people with cancer diagnosed with acute thromboembolism,
including the role of DOACs?
4. What is the appropriate duration of anticoagulation?
5. What is the appropriate treatment strategy in patients with
recurrent VTE on anticoagulation?
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the number of cancers subsequently diagnosed (5.0 vs.
3.7 %, respectively) or in overall mortality (8.3 vs. 7.6 %,
respectively) during 2.5 years of follow up [13]. The only
reported randomized controlled trial included patients with
negative limited occult cancer screening and randomized
them to no further testing or additional testing [14]. The
extensive screening strategy had a sensitivity of 93 % and
increased detection of the number of cases of early-stage
cancers (T1–2, N0) (64 vs. 20 %, p = 0.047). An absolute
risk reduction of cancer-related mortality of 1.9 % in favor
of the extensive screening group during the 2-year follow-
up period was reported. Although the lack of statistical
significance of the cancer-related mortality difference
might be due to lack of power, methodological limitations
and implied possible lead-time bias undermine the results.
Furthermore, the components of an ideal extensive occult
cancer screening program are still unknown. A decision
analysis using the data from the randomized trial described
above and a meta-analysis have reported that limited occult
cancer screening in combination with a CT abdomen/pelvis
had the best yield [9, 15]. However, the complication rates,
cost-effectiveness and difference in morbidity and mortal-
ity associated with this extensive screening could not be
determined [9].
The National Institute for Health Care Excellence
(NICE) guidelines on managing VTE suggest that all
patients diagnosed with unprovoked VTE should be given a
physical examination, chest X-ray, basic laboratory inves-
tigations, and urinanalysis. A CT abdomen/pelvis and,
mammography for women, is also suggested in patients
aged over 40 [16]. However, these recommendations are
controversial as it remains unclear whether extensive
occult cancer screening and earlier cancer detection
improves morbidity, mortality and quality of life in patients
with newly diagnosed VTE. Finally, extensive screening
carries a significant economic cost and can induce signifi-
cant psychological burden. Further clinical trials are
required to assess the risks and benefits of an extensive
occult cancer screening program in patients with unpro-
voked VTE.
Guidance Statements
• Patients with unprovoked VTE should undergo a
through medical history and physical examination,
basic laboratory investigations (complete blood counts,
metabolic profile and liver function tests) and chest
X-ray.
• We suggest that if not up-to-date, patients undergo age-
and gender-specific cancer screening (i.e. cervical,
breast, prostate and colon).
(2) How can high-risk cancer patients be identified for
primary thromboprophylaxis?
Although it is commonly stated that cancer patients are
at high risk for VTE, there is significant variation in risk
amongst subgroups of this population. In a large recent
systematic review of studies, the VTE estimate for the
general cancer population was approximately 13 per 1000
person-years (95 % CI 7–23) [17]. In patients with meta-
static disease or those receiving thrombogenic regimens the
risk was 68 per 1000 person-years (95 % CI 48–96) and as
high as 200 per 1000 person-years (95 % CI 162–247)
amongst patients with primary brain tumors. Discriminat-
ing between low- and high-risk patients is therefore crucial
to optimize the risk-benefit ratio of thromboprophylaxis.
Clinical risk factors, biomarkers or combinations of the
two can be used to estimate VTE risk. Clinical risk factors
include the primary site of cancer (with highest rates
observed in patients with primary brain tumors and cancers
of the pancreas, stomach, liver, lungs and kidneys and
hematologic malignancies including lymphomas and
myeloma), advanced stage and therapeutic interventions
including surgery, type of chemotherapy, erythropoiesis-
stimulating agents, and devices such as central venous
catheters and inferior vena cava filters (reviewed in [1]). It
should be noted that the advent of novel ‘‘targeted’’ anti-
cancer therapies to supplement or replace traditional
chemotherapy-based regimens has not reduced the risk of
VTE. Indeed, drugs targeting angiogenesis such as beva-
cizumab, sunitinib, sorafenib, the multi-targeted tyrosine
kinase inhibitor ponatinib and the immunomodulator
lenalidomide have been associated with arterial throm-
boembolism [18, 19], immunomodulatory agents such as
thalidomide and lenalidomide have been associated with
very high rates of VTE [20], and anti-epidermal growth
factor antibodies such as cetuximab and panitumumab have
also recently been associated with VTE [21]. A variety of
candidate biomarkers have also been associated with VTE
in malignancy. These include elevated platelet and leuko-
cyte counts, decreased hemoglobin, elevated D-dimer,
elevated prothrombin activation products, elevated soluble
P-selectin, thrombin generation and elevated levels of TF-
bearing microparticles (TFMP) [22].
Despite the multitude of reports linking cancer-associ-
ated VTE to individual risk factors or biomarkers, it should
be noted that many of the published studies are univariate
or limited multivariate analyses. Strategies utilizing such
individual factors to enroll patients onto clinical trials of
thromboprophylaxis have not yielded the event rates that
would have been predicted. For instance, in two large trials
of outpatient prophylaxis, patients were selected based only
on primary site and advanced stage; in these studies, event
rates in the placebo arm ranged from 3.4 to 3.9 % and even
though the studies found a statistically significant reduction
with thromboprophylaxis in symptomatic VTE, results
were not adopted by the oncology community due to low
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event rates [23, 24]. Based on this experience, the latest
ASCO guidelines recommend against the use of single risk
factors to identify high-risk patients [7].
The ASCO panel and other guidelines including NCCN
and ESMO instead recommend the use of a validated risk
assessment tool to discriminate between high- and low-risk
patients (Table 2). This risk score was originally derived
from a development cohort of 2701 patients and then val-
idated in an independent cohort of 1365 patients from a
prospective registry by Khorana and colleagues (the so-
called ‘‘Khorana Score’’) [25]. Subsequently, the Score was
externally validated prospectively by the Vienna CATS
consortium and multiple retrospective cohort studies [1,
26].
How can risk stratification be utilized to select patients
for outpatient thromboprophylaxis? An updated Cochrane
systematic review of multiple randomized trials of outpa-
tient prophylaxis in malignancy found that LMWH sig-
nificantly reduced symptomatic VTE (RR 0.62, 95 % CI
0.41–0.93) but with a relatively high number needed to
treat (NNT = 60) [27]. LMWH was associated with a
60 % non-significant increase in major bleeding (RR 1.57,
95 % CI 0.69–3.60). Thus patients with higher absolute
risk of VTE would derive greater benefit and conversely
patients with a lower baseline risk would derive less benefit
or no benefit. Proof of this concept comes from subgroup
analyses of the two largest randomized trials. Rates of VTE
in high-risk patients (Khorana Score C3) enrolled in
PROTECHT were 11.1 % in the placebo arm and 4.5 % in
the nadroparin arm (NNT = 15, compared to 77 for low-
and intermediate-risk patients) [28]. Similarly, in a per-
protocol subgroup analysis of SAVE-ONCO, NNT was 25
for high-risk patients compared to 333 for low-risk patients
[29]. No differences were observed in bleeding rates
between high- and low-risk patients. Based on these find-
ings, prophylaxis is not recommended in unselected gen-
eral cancer patients (i.e. without risk stratification) or in
those with a high risk of bleeding (e.g. primary brain
tumors).
One niche population in this regard is patients with
multiple myeloma receiving imid-based regimens. In an
updated Cochrane meta-analysis, LMWH was associated
with a significant reduction in symptomatic VTE when
compared with the vitamin K antagonist warfarin (RR 0.33,
95 % CI 0.14–0.83), while the difference between LMWH
and aspirin was not statistically significant (RR 0.51, 95 %
CI 0.22–1.17) [27].
It should be noted that there are other settings in which
pharmacologic thromboprophylaxis is generally recom-
mended by major guidelines panels. These include hospi-
talized cancer patients with other risk factors such as an
acute medical illness or recent surgery. In acutely ill
medical inpatients, unfortunately, no cancer-specific clini-
cal trials have been conducted; recommendations are
therefore made based upon extrapolation of data from
randomized trials that included only a small minority of
cancer patients [30]. Extended prophylaxis with LMWH
for up to 4 weeks postoperatively should be considered for
patients undergoing major abdominal or pelvic surgery for
cancer who have high-risk features such as restricted
mobility, obesity or history of VTE [7]. There are currently
no substantial data on the use of DOACs in the prophylaxis
setting; ongoing studies are addressing this issue.
Guidance Statements (See Table 3 for dosing): Rec-
ommendations are made assuming no existing contraindi-
cations to pharmacologic prophylaxis.
• We suggest against routine thromboprophylaxis in
unselected and low-risk cancer outpatients. We also
suggest against routine thromboprophylaxis in patients
with high risk for bleeding (e.g. primary brain tumors).
• We suggest consideration of outpatient thrombopro-
phylaxis with LMWH in high-risk (Khorana Score C3
or advanced pancreas) cancer outpatients receiving
chemotherapy and with aspirin or LMWH in patients
with myeloma receiving imid-based regimens.
• We suggest routine consideration of inpatient throm-
boprophylaxis with LMWH or unfractionated heparin
Table 2 Predictive model for
VTE according to Khorana et al.
[25]
Patient characteristics Risk score
Site of cancer
Very high risk (stomach, pancreas) 2
High risk (lung, lymphoma, gynecologic, bladder, testicular) 1
Prechemotherapy platelet count C350,000/mm3 1
Hemoglobin level less than 10 g/dl or use of red cell growth factors 1
Prechemotherapy leukocyte count[11,000/mm3 1
Body mass index C35 kg/m2 or more 1
High-risk score C3
Intermediate risk score 1–2
Low-risk score 0
84 A. A. Khorana et al.
123




Unfractionated heparin 5000 U once every 8 hc
Dalteparin 5000 U once daily
Enoxaparin 40 mg once daily
Fondaparinux 2.5 mg once daily
Surgical patientsb,d
Unfractionated heparin 5000 U 2–4 h preoperatively and once every 8 hours thereafter or 5000 U 10–12 h
preoperatively and 5000 U once daily thereafterc
Dalteparin 2500 U 2–4 h preoperatively and 5000 U once daily thereafter or 5000 U 10–12 h
preoperatively and 5000 U once daily thereafter
Enoxaparin 20 mg 2–4 h preoperatively and 40 mg once daily thereafter or 40 mg 10–12 h
preoperatively and 40 mg once daily thereafter
Fondaparinux 2.5 mg qd beginning 6–8 h postoperatively
Treatment of established VTE
Initial
Unfractionated heparine 80 U/kg IV bolus, then 18 U/kg per hour IV; adjust dose based on aPTTh
Dalteparine,g,h 100 U/kg once every 12 h; 200 U/kg once daily
Enoxoparine,g,h,i 1 mg/kg once every 12 h; 1.5 mg/kg once daily
Tinzaparine,g,h,j 175 U/kg once per day
Fondaparinuxe,g \50 kg, 5.0 mg once daily; 50–100 kg, 7.5 mg once daily;[100 kg, 10 mg once daily
Long termk
Dalteparinh,g 200 U/kg once daily for 1 month, then 150 U/kg once daily
Enoxaparing,h,i 1.5 mg/kg once daily; 1 mg/kg once every 12 h
Tinzaparinh,j 175 U/kg once daily
Warfarin Adjust dose to maintain INR 2–3
aPTT activated partial thromboplastin time, FDA US Food and Drug Administration, INR international normalized ratio, IV intravenous, LMWH
low-molecular weight heparin, VTE venous thromboembolism
a All doses are administered as subcutaneous injections except as indicated
b Duration for medical patients is length of hospital stay or until fully ambulatory; for surgical patients, prophylaxis should be continued for at
least 7–10 days. Extended prophylaxis for up to 4 weeks should be considered for high-risk patients
c Unfractionated heparin 5000 U every 12 h has also been used but appears to be less effective
d When neuraxial anesthesia or analgesia is planned, prophylactic doses of once-daily LMWH should not be administered within 10–12 h before
the procedure/instrumentation (including epidural catheter removal). After surgery, the first dose of LMWH can be administered 6–8 h post-
operatively. After catheter removal the first dose of LMWH can be administered no earlier than 2 h afterward. Clinicians should refer to their
institutional guidelines and the American Society of Regional Anesthesia Guidelines for more information
e Parenteral anticoagulants should overlap with warfarin for 5–7 days minimum and continued until INR is in the therapeutic range for 2
consecutive days
f Unfractionated heparin infusion rate should be adjusted to maintain the aPTT within the therapeutic range in accordance with local protocol to
correspond with a heparin level of 0.3–0.7 U/mL using a chromogenic Xa essay
g Dependent on significant renal clearance; avoid in patients with creatinine clearance B30 mL/min or adjust dose based on anti-factor Xa levels
h Optimal dose unclear in patients[120 kg
i Twice-daily dosing may be more efficacious than once-daily dosing for enoxaparin based on post hoc data
j This drug is not available in the United States
k Total duration of therapy depends on clinical circumstances. See Clinical Question 4, section entitled ‘‘Initial Long-Term Treatment Up to 6
Months,’’ for more detailed discussion
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in cancer patients hospitalized with an acute medical
illness.
• We suggest inpatient thromboprophylaxis with LMWH
or unfractionated heparin in cancer patients undergo-
ing major surgery.
• We suggest post-operative thromboprophylaxis with
LMWH for up to 4 weeks in patients undergoing major
abdominal or pelvic surgery for cancer with high-risk
features such as immobility, obesity and history of VTE.
(3) What is the appropriate immediate and long-term
treatment for people with cancer diagnosed with
acute VTE, including the role of DOACs?
Cancer patients with VTE have higher rates of compli-
cations, including a 12 % annual risk of bleeding compli-
cations and up to a 21 % annual risk of recurrent VTE
while on warfarin therapy [3]. Furthermore, epidemiologic
and other studies have suggested that cancer-associated
VTE may be relatively resistant to warfarin. Therefore
LMWHs were evaluated as an alternate, extended-therapy
option to warfarin. The CLOT trial reported by Lee et al.
randomized 676 cancer patients with VTE to receive initial
dalteparin followed by 6 months of either dalteparin or
warfarin with target INR 2.5 [31]. Fifteen percent of
patients treated with warfarin developed recurrent VTE
compared to 7.9 % of patients treated with dalteparin
[hazard ratio (HR) 0.48, 95 % CI 0.30–0.77; NNT = 12).
This study established the superiority of LMWH for long-
term anticoagulation in cancer patients. This and subse-
quent smaller studies have been evaluated in a Cochrane
systematic review that further supports the initial findings
of the CLOT study [32]. A recent presentation of the
CATCH trial, the largest treatment study of cancer-asso-
ciated thrombosis, largely confirms these initial findings
[33, 34]. In this global, randomized phase III clinical trial,
900 patients were randomized to either tinzaparin 175 IU/
kg once daily for 6 months or initial tinzaparin 175 IU/kg
once daily for 5–10 days overlapped and followed by dose-
adjusted warfarin (target INR 2–3) for 6 months. Over the
6-month trial period, 31 patients (6.9 %) in the tinzaparin
arm experienced recurrent VTE compared with 45 (10 %)
in the warfarin arm [HR 0.65 (95 % CI 0.41–1.03;
p = 0.07)]. Symptomatic non-fatal DVT occurred in 12
patients (2.7 %) in the tinzaparin arm and 24 (5.3 %) in the
warfarin arm [HR 0.48 (95 % CI 0.24–0.96); p = 0.04].
Significantly fewer patients experienced clinically relevant
non-major bleeding with tinzaparin than warfarin (11 vs.
16 %, respectively; p = 0.03). There were no differences
in rates of major bleeding, non-fatal PE or mortality
between the two arms. Current guidelines recommend
long-term anticoagulation with LMWH for cancer patients
with VTE as the preferred approach and results of this
latest trial support this strategy [7].
The past few years have seen the emergence of several
DOACs, which have been shown to be comparable to
conventional therapy with warfarin for the acute treatment
of VTE. Four agents (rivaroxaban, dabigatran, apixaban
and edoxaban) have received regulatory approval for the
treatment of VTE. However, none of these agents were
tested in cancer-specific populations and, in all of the
treatment studies, patients in the control arm received
vitamin K antagonists (VKA) rather than LMWH. The
definition of ‘‘active cancer’’ was also not consistent across
studies, and some included cancer survivors. Therefore, the
efficacy and safety of DOACs in patients with cancer-as-
sociated VTE remains uncertain. Indeed, the European
Medecines Agency label for apxiaban notes that its efficacy
and safety in patients with active cancer has not been
established [35]. A recent meta-analysis evaluated 9 ran-
domized trials involving 2310 patients with cancer-asso-
ciated thrombosis treated with DOACs [36]. In comparison
to VKA, LMWH showed a significant reduction in recur-
rent VTE events (RR: 0.52; 95 % CI 0.36–0.74) whereas
DOACs did not (RR: 0.66; 95 % CI 0.39–1.11) (Fig. 1).
LMWH was associated with a non-significant increase in
the risk of major bleeding (RR: 1.06; 95 % CI 0.5–2.23)
whereas DOACs showed a non-significant reduction (RR:
0.78; 95 % CI 0.42–1.44) compared to VKA. Annualized
risks of recurrent VTE and major bleeding among patients
randomized to VKA were higher in the LMWH studies as
compared to the studies assessing DOACs, suggesting that
a higher risk cancer population was enrolled in the LMWH
studies. Ongoing and planned studies aim to determine the
relative safety and efficacy of DOACs in cancer-associated
VTE compared with LMWH.
Incidental VTE, defined as VTE discovered on scans
ordered for reasons other than suspected VTE (typically
cancer staging or restaging) is an emerging major con-
tributor to the burden of cancer-associated VTE. Although
management of these events remains controversial, retro-
spective studies have found similar risks of mortality and
recurrent VTE between patients with symptomatic and
incidental PE [37–40]. Given the high risk of future,
symptomatic VTE in these patients, many clinicians are
reluctant to manage them without anticoagulation. How-
ever, there is some evidence that patients with isolated,
incidental subsegmental PE may not need anticoagulant
treatment [41].
Further confusion regarding incidental VTE surrounds
the diagnosis of incidental visceral vein thrombi. Indeed,
the majority of incidental VTE in malignancy involves
visceral veins [38]. Visceral vein thrombi include portal,
mesenteric, splenic, renal and gonadal vein thrombi. In a
cohort study of gastrointestinal cancer patients, 100 % of
visceral vein thrombi were incidentally discovered com-
pared to 35 % of PE [42]. The consequences of incidental
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visceral vein thrombi are less well understood, although
there appears to be at least an independent association with
mortality [(HR) 2.6, 95 % CI 1.6–4.2] in patients with
pancreas cancer [38]. It is unclear whether this association
with mortality can be ameliorated by anticoagulation. Due
to lack of evidence, decisions to treat or not treat visceral
vein thrombi are made inconsistently, largely based on
provider opinion and anecdotal experience. In a study by
Ageno and colleagues, one-half of abdominal vein thrombi
were not treated with anticoagulation [43]. Prospective
clinical trials data in this setting are sorely lacking.
Guidance Statements (see Table 3 for dosing):
• We suggest that patients with active cancer (i.e. known
disease or receiving some form of anti-cancer therapy)
and VTE be treated with LMWH for at least 6 months.
Fig. 1 Forest plot of relative
risks across clinical trials
comparing (a) DOAC versus
VKA and (b) LMWH alone
versus VKA for recurrent
cancer-associated VTE. The
definition of active cancer and
therefore of the study
population varied across trials
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• We suggest that patients with incidentally diagnosed
DVT or PE be treated similarly to patients diagnosed
with VTE based on symptoms i.e., with at least
6 months of LMWH monotherapy, with the exception
of isolated subsegmental PE where decisions can be
made on a case-by-case basis. We further suggest that
treatment decisions in patients with incidentally diag-
nosed visceral vein thrombi be made on a case-by-case
basis.
(4) What is the appropriate duration and preferred agent
for anticoagulation in cancer patients with VTE?
The optimal duration of anticoagulation is not known as
this has not been formally assessed beyond 6 months. In
current practice, the consensus is to continue anticoagula-
tion for at least 6 months and then reassess the need for
continuing anticoagulation. In those with ongoing risk
factors, such as metastatic or progressive disease or
ongoing systemic chemotherapy, continuing anticoagula-
tion may be indicated to prevent recurrence. Conversely, in
those without ongoing risk factors, the risk of recurrent
VTE is likely sufficiently low to justify stopping
anticoagulation.
Anticoagulation may be continued beyond 6 months if
there is active malignancy and/or active, ongoing anti-
neoplastic therapy. Results from a post-marketing study of
extended treatment with dalteparin in patients with
malignancy (DALTECAN) were recently reported. Of 334
patients, 109 (33 %) completed 12 months of dalteparin.
Median treatment duration was 214 days. The highest
major bleeding rate was in the first month of dalteparin
therapy at 3.6 %, declining to 1.1 % during months 2–6,
and 0.7 % over months 7–12 (p = 0.39 for months 2–6 vs.
7–12). The incidence of new or recurrent VTE was 11.1 %;
again, highest for month 1 at 5.7 %, falling to 0.8 % per
month for months 2–6 and 0.7 % per month for months
7–12. These data suggest that extended treatment is feasi-
ble and major bleeding is not a substantial concern; how-
ever, risk-benefit ratio is unclear given relatively low rates
of recurrent VTE past initial months of treatment. Given
lack of randomized trial evidence, the best agent in this
setting is unknown.
Guidance Statements
• Anticoagulation with LMWH monotherapy should be
prescribed for a minimum period of 6 months after
diagnosis of cancer-associated VTE. Anticoagulation
therapy should be continued beyond 6 months if a
patient has active malignancy (i.e. persistent malignant
disease) or if ongoing anti-cancer therapy is planned.
• For patients at low risk of recurrence we suggest that
anticoagulation be discontinued after 6 months in the
absence of active malignancy (i.e. patients are cured or
in complete remission), provided that no anti-cancer
therapy is ongoing or planned.
• For patients at high risk of recurrence we suggest that
anticoagulation be continued but with periodic re-
evaluation of risks and benefits.
(5) What is the appropriate treatment strategy in patients
with recurrent VTE on anticoagulation?
As noted earlier, recurrent VTE is not infrequent even in
patients receiving appropriate anticoagulation in the setting
of malignancy. Unfortunately, there are no randomized
trials to provide an evidence-based approach. A recent
paper and an ISTH guidance statement have described
empiric approaches to this clinical problem [44, 45]. In
general, LMWH monotherapy is considered the preferred
approach. If patients are already on LMWH, dose escala-
tion should be considered [44]. In a retrospective cohort
study, the weight-adjusted dose of LMWH was increased
by 20–25 % for at least 4 weeks. Patients on maintenance
dose of LMWH were increased to full therapeutic dose for
6–12 weeks. Only 8.6 % of patients had a second recurrent
VTE with this approach and 4.3 % had bleeding
complications.
Inferior vena cava (IVC) filters should only be used
temporarily in patients with acute thrombosis who have
absolute contraindications to anticoagulation. In a
prospective randomized study of 200 patients (including 56
with cancer), patients who received filters had short-term
protection from PE but higher rates of DVT and filter-site
thrombosis compared to those randomized to no filters
(20.8 vs. 11.6 %, OR 1.87, 95 % CI 1.10–1.38). No short-
or long-term survival benefit from IVC filter placement
was seen. The potential risks of IVC filter placement are
highlighted by non-randomized cohort studies that found
IVC filters were associated with increased metastases and
reduced survival in cancer patients [46].
Guidance Statements
• We suggest that cancer patients with symptomatic
recurrent VTE despite therapeutic anticoagulation with
an agent other than LMWH be transitioned to thera-
peutic LMWH, assuming no contraindications to
LMWH.
• We suggest that cancer patients with symptomatic
recurrent VTE despite optimal anticoagulation with
LMWH continue with LMWH at a higher dose, starting
at an increase of *25 % of the current dose or
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resuming the therapeutic weight-adjusted dose if the
patient was receiving a non-therapeutic dose at the
time of recurrence.
• We suggest against the use of IVC filters except in the
presence of absolute contraindications to pharmaco-
logic anticoagulation (e.g. active bleeding). If neces-
sary, retrievable filters should be used and a plan
created to retrieve the filter when appropriate.
Conclusion
VTE is an important cause of morbidity and mortality in
patients with malignancy. In this chapter, we have identi-
fied important clinical questions and attempted to provide
recommendations to clinicians based on analysis of exist-
ing data, systematic reviews and meta-analyses as well as
consensus between authors (Table 4). Many important
Table 4 Summary of guidance statements
Question Guidance statement
1. What is the appropriate workup to
search for occult malignancy in patients
with idiopathic VTE?
Patients with unprovoked VTE should undergo a through medical history and physical examination,
basic laboratory investigations (complete blood counts, metabolic profile and liver function tests)
and chest
X-ray
We suggest that if not up-to-date, patients undergo age- and gender-specific cancer screening (i.e.
cervical, breast, prostate and colon)
2. How can high-risk cancer patients be
identified for primary
thromboprophylaxis?
Recommendations are made assuming no existing contraindications to pharmacologic prophylaxis
We suggest against routine thromboprophylaxis in unselected and low-risk cancer outpatients. We
also suggest against routine thromboprophylaxis in patients with high risk for bleeding (e.g.
primary brain tumors)
We suggest consideration of outpatient thromboprophylaxis with LMWH in high-risk (Khorana
Score C3 or advanced pancreas) cancer outpatients receiving chemotherapy and with aspirin or
LMWH in patients with myeloma receiving imid-based regimens
We suggest routine consideration of inpatient thromboprophylaxis with LMWH or unfractionated
heparin in cancer patients hospitalized with an acute medical illness
We suggest inpatient thromboprophylaxis with LMWH or unfractionated heparin in cancer patients
undergoing major surgery
We suggest post-operative thromboprophylaxis with LMWH for up to 4 weeks in patients
undergoing major abdominal or pelvic surgery for cancer with high-risk features such as
immobility, obesity and history of VTE
3. What is the appropriate immediate and
long-term treatment for people with
cancer diagnosed with acute
thromboembolism, including the role of
DOACs?
We suggest that patients with active cancer (i.e. known disease or receiving some form of anti-
cancer therapy) and VTE be treated with LMWH for at least 6 months
We suggest that patients with incidentally diagnosed DVT or PE be treated similarly to patients
diagnosed with VTE based on symptoms i.e., with at least 6 months of LMWH monotherapy, with
the exception of isolated subsegmental PE where decisions can be made on a case-by-case basis.
We further suggest that treatment decisions in patients with incidentally diagnosed visceral vein
thrombi be made on a case-by-case basis
4. What is the appropriate duration of
anticoagulation?
Anticoagulation with LMWH monotherapy should be prescribed for a minimum period of 6 months
after diagnosis of cancer-associated VTE. Anticoagulation therapy should be continued beyond
6 months if a patient has active malignancy (i.e. persistent malignant disease) or if ongoing anti-
cancer therapy is planned
For patients at low risk of recurrence we suggest that anticoagulation be discontinued after 6 months
in the absence of active malignancy (i.e. patients are cured or in complete remission), provided
that no anti-cancer therapy is ongoing or planned
For patients at high risk of recurrence we suggest that anticoagulation be continued but with periodic
re-evaluation of risks and benefits
5. What is the appropriate treatment
strategy in patients with recurrent VTE
on anticoagulation?
We suggest that cancer patients with symptomatic recurrent VTE despite therapeutic anticoagulation
with an agent other than LMWH be transitioned to therapeutic LMWH, assuming no
contraindications to LMWH
We suggest that cancer patients with symptomatic recurrent VTE despite optimal anticoagulation
with LMWH continue with LMWH at a higher dose, starting at an increase of *25 % of the
current dose or resuming the therapeutic weight-adjusted dose if the patient was receiving a non-
therapeutic dose at the time of recurrence
We suggest against the use of IVC filters except in the presence of absolute contraindications to
pharmacologic anticoagulation (e.g. active bleeding). If necessary, retrievable filters should be
used and a plan created to retrieve the filter when appropriate
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issues remain to be addressed; in particular, how best to
enhance appropriate utilization of outpatient thrombopro-
phylaxis and how to integrate the emerging class of
DOACs into prevention and treatment of malignancy.
Considering the intense scientific interest in this area that
has emerged in the past decade, we are cautiously opti-
mistic that the scientific community can continue to iden-
tify ways to enhance patient-centered care and reduce the
public health burden of this important and consequential
complication of malignancy and its treatments.
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